Ofatumumab – B Cell Therapy
Cumulative Pregnancy Outcomes in Patients With Multiple Sclerosis Following Maternal Exposure to Ofatumumab: Results From the Novartis Safety Database
Bove R. et al
Poster: P510
Poster: P510
B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights From ASCLEPIOS I and II Trials
Cross AH. et
al
Poster: P098
Poster: P098
Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-Naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels
Pardo G. et al
Poster: P031
Poster: P031
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients With Relapsing Multiple Sclerosis: Results From Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials
Cross AH. et
al
Poster: P037
Poster: P037
Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results From the Phase 3 ASCLEPIOS I/II Trials
Delgado S. et
al
Poster: P036
Poster: P036
Prognostic Value of On-Treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People With Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials
Leist T. et al
Poster: P032
Poster: P032
Ofatumumab Attenuates Cortical Microglial Activity in Patients With Relapsing Forms of Multiple Sclerosis Following B-cell depletion: Results From a 9-month Study
Singhal T. et
al
Poster: P222
Poster: P222
Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results from Structured Interviews
Alvarez E. et
al
Poster: P437
Poster: P437
Ofatumumab in Different RMS Patient Populations in Everyday Clinical Practice in Germany
Nelles G. et
al
Poster: P467
Poster: P467
An Expert Delphi Panel to Understand Potential Ofatumumab Injection-Related Reactions Among Patients with Relapsing Forms of Multiple Sclerosis
Saidha S. et
al
Poster: P157
Poster: P157
Immune Response to Influenza Vaccine in Patients With Relapsing Multiple Sclerosis Treated With Ofatumumab: Results From an Open-Label, Multicenter, Phase 4 Study
Subei A. et al
Poster: P272
Poster: P272
Real-world Change in Annualized Relapse Rate Following Initiation of Ofatumumab in Patients with Multiple Sclerosis
Tai MH. et al
Poster: P489
Poster: P489
KAIROS: Ofatumumab in Patients With Relapsing Remitting Multiple Sclerosis who Previously Received Another Disease-modifying Therapy
Bischof F. et
al
Poster: P486
Poster: P486
Siponimod
Longitudinal Observation of SPMS Patients Treated with Siponimod in
Germany – Three Years Interims Data from Real World Study AMASIA
Hoffmann O. et
al
Poster: P376
Poster: P376
MS portfolio
A Prospective Data Collection to Evaluate Utility and Added Value of Serum NfL in Multiple Sclerosis - First Interim Insights from NeofiLos
Ziemssen T. et
al
Poster: P033
Poster: P033
NeofiLos – Rationale, Design, Patient Characteristics (First Interim Data)
Ziemssen T. et
al
Poster: P034
Poster: P034
Eye Movement Biomarkers for Classification of Multiple Sclerosis Progression vs Non-Progression in a Cohort of Multiple Sclerosis Patients
Giacomini PS. et
al
Poster: P043
Poster: P043
MLR ID: 416384